Dark

Check out our Level2View

AHAC
Alpha Healthcare Acquisition Corp. Class A Common Stock
stock NASDAQ

Inactive

Aug 26, 2021

10.96USD+7.980%(+0.81)298,128

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD-100.000%(-10.15)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

Aug 28, 2021

01:06PM EDT The Past Week's Notable Insider Buys: Callon Petroleum, Cricut, Krispy Kreme And More Benzinga

Aug 26, 2021

04:05PM EDT Humacyte Announces Successful Closing of Business Combination with GlobeNewswire Inc

Aug 24, 2021

01:00PM EDT Alpha Healthcare Acquisition Announces Shareholder Approval Of Business Combination With Humacyte Benzinga

12:59PM EDT Alpha Healthcare Acquisition Corp. Announces Shareholder Approval GlobeNewswire Inc

Aug 17, 2021

07:30AM EDT -- Appoints proven commercial leader B.J. Scheessele as Chief Commercial Officer -- In-house Durham, N.C. facility is operational and supplying clinical trial material produced in commercial-scale manufacturing system -- Companys proprietary modular manufacturing systems can produce an estimated 40,000+ vessels annually in current facility when scaled up GlobeNewswire Inc

Aug 13, 2021

08:11AM EDT Alpha Healthcare And Humacyte Announce Nominees For Election To Post-Merger Public Company Board Of Directors RTTNews

Aug 11, 2021

07:38AM EDT Alpha Healthcare Acquisition Corp. Combination Partner Humacyte Highlights Publication Of In Vivo Data On Biovascular Pancreas Transplantation For The Treatment Of Type 1 Diabetes Benzinga

07:30AM EDT -- Data demonstrate biovascular pancreas may have the potential to provide an effective and safe method for pancreatic islet cell transplantation for the treatment of type 1 diabetes -- Data published in the Journal of Tissue Engineering GlobeNewswire Inc

Jul 22, 2021

07:30AM EDT Humacyte Presents Potential of Functional Lung Engineering at GlobeNewswire Inc

Jul 20, 2021

10:14AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2021 Benzinga

07:59AM EDT Benchmark Initiates Coverage On Alpha Healthcare with Buy Rating, Announces Price Target of $18 Benzinga

Jun 11, 2021

03:03PM EDT -- Partnership expanded to include vascular trauma repair outside of the United States. -- Fresenius Medical Care is a leading participant in fully committed PIPE financing transaction. GlobeNewswire Inc

07:33AM EDT Alpha Healthcare Acquisition Corp. SPAC Merger Partner, Humacyte, Reports Expansion Of Strategic Global Partnership With Fresenius Medical Care Benzinga

07:30AM EDT -- Partnership expanded to include vascular trauma repair outside of the United States. -- Fresenius Medical Care will adopt the HAV as a standard of care in patients who will benefit from clinical and economic perspectives. -- Fresenius Medical Care is a leading participant in fully committed PIPE financing transaction. GlobeNewswire Inc

Jun 8, 2021

07:30AM EDT -- Laboratory and preclinical models demonstrate biovascular pancreas platform technology may provide method to transplant islet cells that produce insulin in Type 1 diabetes patients -- Data presented at American Transplant Congress 2021 Virtual Connect GlobeNewswire Inc

Jun 4, 2021

07:30AM EDT Humacyte to Provide Investor Update on June 7 GlobeNewswire Inc

May 26, 2021

07:30AM EDT Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that the company has received a 2021 Life Sciences Award from the Triangle Business Journal. GlobeNewswire Inc

May 25, 2021

03:35PM EDT EXCLUSIVE: Humacyte, Alpha Healthcare CEOs Talk SPAC Deal, Technology, Trials On 'SPACs Attack' Benzinga

11:46AM EDT Humacyte CEO Dr. Laura Niklason Says Vascular Trauma Trial Is Still Underway, Anticipates filing BLA Application Sometime In 2022; If This Were Case, Would Expect First Approval Sometime In 2023 Benzinga

11:46AM EDT Humacyte CEO Dr. Laura Niklason Says anticipates Phase 3 Trial In Dialysis Access Should Complete Enrollment By End Of 2021, Would Get Topline Results A Little More Than a Year After That Benzinga

11:31AM EDT Humacyte CEO Dr. Laura Niklason Says Co Has Phase 2 Trials Underway For Vascular Disease In The Legs, Especially For Patients Facing Amputation Benzinga

11:30AM EDT Humacyte CEO Dr. Laura Niklason Says Co. Has Phase 3 Trials Underway For Vascular Trauma And Kidney Failure, Says These Are First Two Conditions Co. Anticipates Gaining Approval For Benzinga

11:24AM EDT Alpha Healthcare CEO Rajiv Shukla Says Humacyte Stood Out; Cites 'Extensive Pipeline' And Large Market Opportunities; Says Investment Thesis Is To Find Companies With Large Addressable Market And Lead In That Market Benzinga

11:22AM EDT Humacyte CEO Dr. Laura Niklason Said Considered SPAC And IPO Pathways, Says SPAC Decision Was Due To Experienced Organization At Alpha; Says SPAC Route Also Allows Co. To Interact Closely With Investors Benzinga

09:47AM EDT Exclusive: Alpha Healthcare CEO, Rajiv Shukla And Humacyte CEO, Dr. Laura Niklason To Appear On Benzinga's 'SPACs Attack' Show At 11:15 a.m. EDT Benzinga

May 24, 2021

04:03PM EDT Exclusive: Alpha Healthcare CEO, Rajiv Shukla And Humacyte CEO, Dr. Laura Niklason To Appear On Benzinga's 'SPACs Attack' Show At 11:15 a.m. EDT On Tuesday Benzinga

May 21, 2021

07:30AM EDT -- Laboratory and pre-clinical models of whole-lung engineering inform roadmap for building a functional lung alveolus, which is the key building block for making a functional lung -- Data presented at 38th Annual Meeting of the Japanese Association for Chest Surgery GlobeNewswire Inc

May 19, 2021

04:30PM EDT Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the appointment of Dale Sander as Chief Financial Officer, Chief Corporate Development Officer and Treasurer, effective immediately. Mr. Sander will succeed Doug Blankenship, who is stepping down from the role. GlobeNewswire Inc

Apr 21, 2021

08:05AM EDT Alpha Healthcare Acquisition M&A Partner Humacyte Announces Long-Term Follow-Up Data From Phase 2 Vascular Access Trial Benzinga

08:00AM EDT Humacyte Announces Positive Long-Term Follow-Up Data from Phase 2 GlobeNewswire Inc

Apr 14, 2021

07:30AM EDT Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced the closing of a secured debt financing facility with Silicon Valley Bank for up to $50 million, of which the first $20 million was funded at closing. GlobeNewswire Inc

Apr 9, 2021

10:11AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 9, 2021 Benzinga

09:23AM EDT Lake Street Initiates Coverage On Alpha Healthcare with Buy Rating, Announces Price Target of $20 Benzinga

Mar 11, 2021

07:30AM EST Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, will present at the virtual Oppenheimer 31st Annual Healthcare Conference March 18, 2021, at 8:40 a.m. EDT. GlobeNewswire Inc

Mar 5, 2021

07:30AM EST Humacyte to Present Long-Term Follow-Up Data from Phase 2 Vascular GlobeNewswire Inc

Feb 17, 2021

07:10AM EST Humacyte To Go Public Through Merger With Alpha Healthcare Acquisition Corp. Benzinga

07:00AM EST Humacyte, a Transformative Biotechnology Platform Company Capable GlobeNewswire Inc

Share